Department of General, Visceral and Transplant Surgery Ruprecht-Karls University Heidelberg Germany.
Liver Cancer Centre Heidelberg Ruprecht-Karls University Heidelberg Germany.
BJS Open. 2019 Sep 10;3(6):793-801. doi: 10.1002/bjs5.50217. eCollection 2019 Dec.
Liver resection is the only curative therapeutic option for intrahepatic cholangiocarcinoma (ICC), but the approach to recurrent ICC is controversial. This study analysed the outcome of liver resection in patients with recurrent ICC.
Demographic, radiological, clinical, operative, surgical pathological and follow-up data for all patients with a final surgical pathological diagnosis of ICC treated in a tertiary referral centre between 2001 and 2015 were collected retrospectively and analysed.
A total of 190 patients had liver resection for primary ICC. The 1-, 3- and 5-year overall survival (OS) rates were 74·8, 56·6 and 37·9 per cent respectively. Independent determinants of OS were age 65 years or above (hazard ratio (HR) 2·18, 95 per cent c.i. 1·18 to 4·0; = 0·012), median tumour diameter 5 cm or greater (HR 2·87, 1·37 to 6·00; = 0·005), preoperative biliary drainage (HR 2·65, 1·13 to 6·20; = 0·025) and local R1-2 status (HR 1·90, 1·02 to 3·53; = 0·043). Recurrence was documented in 87 patients (45·8 per cent). The mean(s.d.) survival time after recurrence was 16(17) months. Independent determinants of recurrence were median tumour diameter 5 cm or more (HR 1·71, 1·09 to 2·68; = 0·020), high-grade (G3-4) tumour (HR 1·63, 1·04 to 2·55; = 0·034) and local R1 status (HR 1·70, 1·09 to 2·65; = 0·020). Repeat resection with curative intent was performed in 25 patients for recurrent ICC, achieving a mean survival of 25 (95 per cent c.i. 16 to 34) months after the diagnosis of recurrence. Patients deemed to have unresectable disease after recurrence received chemotherapy or chemoradiotherapy alone, and had significantly poorer survival.
Patients with recurrent ICC may benefit from repeat surgical resection.
肝切除术是治疗肝内胆管细胞癌(ICC)的唯一治愈性治疗选择,但对于复发性 ICC 的治疗方法仍存在争议。本研究分析了复发性 ICC 患者肝切除术的结果。
回顾性收集 2001 年至 2015 年期间在一家三级转诊中心接受最终手术病理诊断为 ICC 的所有患者的人口统计学、影像学、临床、手术病理和随访数据,并进行分析。
共有 190 例患者因原发性 ICC 行肝切除术。1、3、5 年总生存率(OS)分别为 74.8%、56.6%和 37.9%。OS 的独立决定因素为年龄 65 岁或以上(风险比(HR)2.18,95%置信区间(CI)为 1.18 至 4.0;=0.012)、肿瘤直径 5cm 或以上(HR 2.87,1.37 至 6.00;=0.005)、术前胆道引流(HR 2.65,1.13 至 6.20;=0.025)和局部 R1-2 状态(HR 1.90,1.02 至 3.53;=0.043)。87 例患者(45.8%)记录到复发。复发后平均(SD)生存时间为 16(17)个月。复发的独立决定因素为肿瘤直径 5cm 或更大(HR 1.71,1.09 至 2.68;=0.020)、高级别(G3-4)肿瘤(HR 1.63,1.04 至 2.55;=0.034)和局部 R1 状态(HR 1.70,1.09 至 2.65;=0.020)。25 例复发性 ICC 患者接受了根治性重复切除术,在复发后诊断后的平均生存时间为 25(95%CI 为 16 至 34)个月。在复发后被认为无法切除疾病的患者仅接受化疗或放化疗,其生存情况明显较差。
复发性 ICC 患者可能从重复手术切除中获益。